Donovan Decker’s LGMD Journey & Gene Therapy Advocacy
Table of Contents
- Navigating the Challenges of Limb-Girdle Muscular Dystrophy (LGMD): A Patient Advocate’s Journey
- Limb-Girdle Muscular Dystrophy (LGMD): Your Top questions Answered
- What is Limb-Girdle Muscular Dystrophy (LGMD)?
- What are the challenges faced by the LGMD community?
- What are the critical needs for LGMD patients?
- Why is it difficult to find treatment for all LGMD subtypes?
- What is the impact of genetic differences on clinical trials?
- What are the common misconceptions about LGMD?
- How can I raise awareness for Limb-Girdle Muscular Dystrophy (LGMD)?
- Summary of Key Aspects of LGMD
Published:
What is Limb-Girdle Muscular Dystrophy (LGMD)?
Limb-girdle muscular dystrophy (LGMD) encompasses a diverse set of genetic disorders characterized by progressive weakening and wasting of muscles around the hips, shoulders, and limbs. With over 30 identified subtypes, LGMD presents a wide spectrum of symptoms and progression rates. These range from minor mobility impairments to severe complications affecting respiratory and cardiac functions.
Despite its notable impact on those affected, LGMD often receives less attention and fewer resources compared to other neuromuscular conditions like Duchenne muscular dystrophy (DMD). This disparity poses critical challenges for research, treatment development, and ensuring consistent care for the LGMD community.
Donovan Decker Receives MDA Legacy Award
At the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held in Dallas, Texas, from March 16-19, Donovan Decker, a dedicated patient advocate for LGMD, was honored with the MDA Legacy Award for Community impact and Research. Decker, diagnosed with LGMD 47 years ago, began his research involvement with participation in early muscular dystrophy gene therapy safety trials in 1999. Since then, he and his family have tirelessly worked to raise awareness and support research initiatives focused on limb-girdle muscular dystrophy.
Decker reflected on his decades-long journey with LGMD, discussing his motivation for undergoing a groundbreaking gene therapy procedure. He emphasized his commitment to his family and the future of LGMD research. Decker also addressed the challenges faced by the LGMD community, including limited treatment options and the complexities of establishing care standards for a condition with numerous subtypes.He highlighted misconceptions surrounding LGMD and stressed the need for innovation, awareness, and collaboration to improve care and advance therapies for patients.
Insights from Donovan Decker
During the 2025 MDA conference,Donovan Decker shared his experiences and perspectives on living with Limb-Girdle Muscular Dystrophy.
On Receiving the MDA Legacy Award
”Well, being the first time they’ve done this for patients and stuff, it’s a great honor. I’ve worked with MDA for a lot of years—probably the last 35 years or so—and MDA has been really great. It’s just… I guess it’s always nice to be rewarded when you do work, and hopefully, some good will come out of what we’re doing.”
The Decision to Pursue Gene Therapy
Decker’s decision to try gene therapy was deeply rooted in his family’s experience with LGMD.
“When I made the decision, it was really based on my family. Five out of eight kids in my family have limb-girdle muscular dystrophy (LGMD), and I have two nieces with it to. I’m the only male. When I did the gene therapy, all my other sisters who had the disease where married or had children, and I wasn’t.That’s why I did it.”
He added, “I’d do more trials if there were more options out there.” Decker acknowledged the setbacks in research following the death of Jesse Gelsinger, which “hurt research for at least five years from the FDA side, and it hurt fundraising until about 2014.”
Greatest Needs for LGMD Patients
Decker identified the critical needs for LGMD patients from both treatment and care perspectives.
”From a treatment perspective, I think we need more options. There are some drugs in development right now, but it always seems like they want to work on Duchenne first, and then limb-girdle gets left behind. When gene therapy started, it was the limb-girdle groups that led the way, but then we kind of got put on the shelf for years.Now, things are starting up again. A couple of companies are coming into the space for limb-girdle, all using AAV.”
He also highlighted the need for non-viral options, as a significant percentage of the LGMD group cannot be dosed due to high titer levels. “I actually co-founded a company that’s looking into non-viral options. right now, if you have a high titer, you can’t be dosed, and that excludes maybe 30–40% of the limb-girdle group.So, that’s a big need.”
Regarding care, Decker emphasized the importance of establishing specific standards of care for LGMD subtypes. “On the care side,I think we still need more work on establishing standards of care for LGMD… It’s tricky because there are 34 different genes that cause LGMD. Some types, like mine, affect respiratory function—that’s what my three sisters died from, respiratory failure. But other types don’t affect the respiratory system, and some affect the heart. We need standards of care tailored to each subtype, like LGMD 2D or 2A. Right now, they just throw everyone into one group, and that doesn’t work because the differences between subtypes are so drastic.”
Impact of Genetic Differences on Clinical Trials
Decker believes that genetic differences within LGMD pose challenges for clinical trials and drug development.
“I think it does hurt as the patient populations for each subtype are so small. For example, there are only about 1,200 people in the U.S. with LGMD 2D. I’ve always felt that the limb-girdle community built the foundation for gene therapy in muscular dystrophy, but now companies don’t want to invest as there’s no money in it.”
Misconceptions About LGMD
Decker addressed common misconceptions about LGMD,especially its perceived severity.
“To me, the biggest misconception is that because LGMD is slower-progressing, people don’t take it seriously. Some don’t even realize it can be fatal. but it can be, depending on the subtype.In my family, it’s respiratory failure that’s fatal.”
He also noted the issue of lumping all subtypes together, emphasizing that “each gene defect is so different… Because of that, it gets overlooked, and people forget about what’s in the bucket.”
Raising Awareness for Limb-Girdle Muscular Dystrophy
Organizations like the LGMD awareness Foundation, Inc. are dedicated to globally raising awareness of limb-girdle muscular dystrophy (LGMD). Increased awareness is crucial for driving research, improving care standards, and supporting individuals and families affected by this condition.
Limb-Girdle Muscular Dystrophy (LGMD): Your Top questions Answered
What is Limb-Girdle Muscular Dystrophy (LGMD)?
Limb-girdle muscular dystrophy (LGMD) is a group of genetic disorders marked by progressive weakening and wasting of muscles around the hips, shoulders, and limbs.It’s a diverse set of conditions, with over 30 identified subtypes, each with varying symptoms and progression rates. These can range from mild mobility issues to severe complications affecting respiratory and cardiac functions.
What are the challenges faced by the LGMD community?
The LGMD community faces several significant challenges:
Limited treatment options: Compared to other neuromuscular conditions like Duchenne muscular dystrophy (DMD), LGMD has fewer treatment options available. Though some drugs are in advancement, the LGMD community often sees research and development efforts prioritized for other conditions.
Complexities of care: LGMD has numerous subtypes, each caused by different genetic defects. This diversity makes it challenging to establish consistent standards of care tailored to each subtype.
Misconceptions and lack of awareness: There’s a misconception that as LGMD progresses slowly, it’s not as serious as other muscular dystrophies. However, this condition can be fatal, depending on the subtype.
Challenges in clinical trials: The small patient populations for each subtype present considerable challenges for clinical trials and drug development.
What are the critical needs for LGMD patients?
According to Donovan Decker, a patient advocate and MDA Legacy Award recipient, the critical needs for LGMD patients fall into two categories:
Treatment
More treatment options are needed, with a focus on LGMD-specific therapies.
There’s a need for non-viral options, as a significant percentage of the LGMD group cannot be dosed due to high titer levels.
Care
Establishing specific standards of care for each LGMD subtype is crucial.Because there are 34 different genes that cause LGMD, treatments need to be tailored to each condition.
Why is it difficult to find treatment for all LGMD subtypes?
LGMD is a rare condition with many subtypes. As patient populations for each subtype are small, companies don’t always want to invest as it is indeed not profitable.
What is the impact of genetic differences on clinical trials?
The genetic differences within LGMD pose a significant challenge for clinical trials and drug development. The small patient populations for each subtype make it difficult to conduct trials effectively.
What are the common misconceptions about LGMD?
The biggest misconception about LGMD is that its slower progression means the condition is not serious. Some people don’t realize that LGMD,depending on the subtype,can be fatal. In some families, respiratory failure is a fatal outcome. Another issue is the lumping of all subtypes together,as each gene defect is very different and requires different treatments.
How can I raise awareness for Limb-Girdle Muscular Dystrophy (LGMD)?
Organizations like the LGMD Awareness Foundation,Inc. are dedicated to raising awareness of limb-girdle muscular dystrophy (LGMD). Increased awareness is crucial for:
Driving research
Improving care standards
Supporting individuals and families affected by this condition.
Summary of Key Aspects of LGMD
| Aspect | Details |
| :———————- | :————————————————————————————————————————————————– |
| Definition | Genetic disorders causing progressive muscle weakness and wasting in the limb-girdle area (hips, shoulders, and limbs). |
| Subtypes | Over 30 different subtypes, each with varied symptoms and progression rates.|
| Challenges | Limited treatment options, complexities in care standards, misconceptions, and challenges in clinical trials due to small patient populations. |
| Key Needs | More treatment options tailored to specific subtypes, non-viral treatment options, and subtype-specific standards of care. |
| Impact | Can range from minor mobility issues to severe respiratory and cardiac complications. Can be fatal, depending on the subtype. |
| Awareness | Organizations dedicated to raising awareness to drive research, improve care, and support those affected. |